| Literature DB >> 26669861 |
F Patrick O'Hara1, Jose A Suaya2, G Thomas Ray3, Roger Baxter4, Megan L Brown1, Robertino M Mera5, Nicole M Close1, Elizabeth Thomas6, Heather Amrine-Madsen7.
Abstract
A number of molecular typing methods have been developed for characterization of Staphylococcus aureus isolates. The utility of these systems depends on the nature of the investigation for which they are used. We compared two commonly used methods of molecular typing, multilocus sequence typing (MLST) (and its clustering algorithm, Based Upon Related Sequence Type [BURST]) with the staphylococcal protein A (spa) typing (and its clustering algorithm, Based Upon Repeat Pattern [BURP]), to assess the utility of these methods for macroepidemiology and evolutionary studies of S. aureus in the United States. We typed a total of 366 clinical isolates of S. aureus by these methods and evaluated indices of diversity and concordance values. Our results show that, when combined with the BURP clustering algorithm to delineate clonal lineages, spa typing produces results that are highly comparable with those produced by MLST/BURST. Therefore, spa typing is appropriate for use in macroepidemiology and evolutionary studies and, given its lower implementation cost, this method appears to be more efficient. The findings are robust and are consistent across different settings, patient ages, and specimen sources. Our results also support a model in which the methicillin-resistant S. aureus (MRSA) population in the United States comprises two major lineages (USA300 and USA100), which each consist of closely related variants.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26669861 PMCID: PMC4722571 DOI: 10.1089/mdr.2014.0238
Source DB: PubMed Journal: Microb Drug Resist ISSN: 1076-6294 Impact factor: 3.431
Diversity Index Assessment of S
| spa | |||||
|---|---|---|---|---|---|
| spa | spa | ||||
| All | |||||
| All isolates | 366 | 0.820 | 0.787 | 0.890 | 0.797 |
| 95% CI | 0.786–0.853 | 0.753–0.820 | 0.862–0.917 | 0.760–0.834 | |
| Age group | |||||
| Children ≤18 years | 116 | 0.761 | 0.733 | 0.848 | 0.704 |
| 95% CI | 0.680–0.842 | 0.648–0.817 | 0.780–0.915 | 0.609–0.799 | |
| Adults ≥50 years | 250 | 0.837 | 0.795 | 0.899 | 0.818 |
| 95% CI | 0.802–0.872 | 0.761–0.829 | 0.870–0.927 | 0.782–0.855 | |
| Patient setting | |||||
| Inpatient | 68 | 0.875 | 0.786 | 0.91 | 0.812 |
| 95% CI | 0.822–0.928 | 0.719–0.852 | 0.860–0.959 | 0.746–0.878 | |
| Outpatient | 298 | 0.803 | 0.777 | 0.877 | 0.782 |
| 95% CI | 0.762–0.844 | 0.735–0.818 | 0.842–0.911 | 0.735–0.828 | |
| Isolate source | |||||
| Skin | 287 | 0.786 | 0.759 | 0.873 | 0.76 |
| 95% CI | 0.741–0.831 | 0.712–0.805 | 0.836–0.909 | 0.709–0.812 | |
| Nonskin | 79 | 0.876 | 0.797 | 0.918 | 0.835 |
| 95% CI | 0.822–0.930 | 0.734–0.861 | 0.876–0.960 | 0.776–0.895 | |
| Methicillin susceptibility | |||||
| MRSA | 170 | 0.575 | 0.513 | 0.716 | 0.521 |
| 95% CI | 0.497–0.653 | 0.442–0.584 | 0.649–0.784 | 0.445–0.597 | |
| MSSA[ | 196 | 0.925 | 0.902 | 0.969 | 0.929 |
| 95% CI | 0.908–0.943 | 0.885–0.919 | 0.957–0.982 | 0.911–0.947 | |
Of note, despite overlapping 95% CI, MLST STs versus spa types are statistically significantly different at alpha = 0.05.
CC, clonal complex; CI, confidence interval; MLST, multilocus sequence typing; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; spa, staphylococcal protein A; ST, sequence type.
Concordance Between Sequence-Based Typing Clonal Grouping Methods for
| All | |||
| All isolates | 366 | 0.906 | 0.966 |
| 95% CI | 0.886–0.927 | 0.954–0.979 | |
| Age group | |||
| Children ≤18 years | 116 | 0.899 | 0.97 |
| 95% CI | 0.850–0.947 | 0.946–0.996 | |
| Adults ≥50 years | 250 | 0.906 | 0.964 |
| 95% CI | 0.884–0.928 | 0.948–0.979 | |
| Patient setting | |||
| Inpatient | 68 | 0.89 | 0.962 |
| 95% CI | 0.846–0.934 | 0.926–0.998 | |
| Outpatient | 298 | 0.908 | 0.967 |
| 95% CI | 0.884–0.932 | 0.953–0.981 | |
| Isolate source | |||
| Skin | 287 | 0.893 | 0.967 |
| 95% CI | 0.865–0.921 | 0.952–0.982 | |
| Nonskin | 79 | 0.91 | 0.953 |
| 95% CI | 0.866–0.955 | 0.916–0.991 | |
| Methicillin-susceptibility | |||
| MRSA | 170 | 0.801 | 0.971 |
| 95% CI | 0.747–0.855 | 0.947–0.995 | |
| MSSA | 196 | 0.947 | 0.959 |
| 95% CI | 0.934–0.960 | 0.945–0.972 | |
Characteristics of the Two Major Methicillin-Resistant
| spa | spa | spa | spa | |||||
|---|---|---|---|---|---|---|---|---|
| Type/clonal group | ST8 | t008 | CC8 | CC008 | ST5 | t002 | CC5 | CC002 |
| Number of isolates | 105 | 85 | 111 | 111 | 34 | 30 | 42 | 37 |
| % of all MRSA isolates | 61.8% | 50.0% | 65.3% | 65.3% | 20.0% | 17.6% | 24.7% | 21.8% |
| 95% CI | 54.5–69.1% | 42.5–57.5% | 58.1–72.5% | 58.14–72.46% | 14.0–26.0% | 11.9–23.3% | 18.2–31.2% | 15.59–28.01% |
| PVL | ||||||||
| PVL+ | 95.2% | 96.5% | 94.7% | 95.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| 95% CI | 91.1–99.3% | 92.6–100% | 90.5–98.9% | 91.64–99.36% | 0.0–0.4% | 0.0–0.4% | 0.0–0.3% | 0.0–0.3% |
| PVL− | 4.8% | 3.5% | 5.3% | 4.5% | 100.0% | 100.0% | 100.0% | 100.0% |
| 95% CI | 0.7–8.9% | −0.4–7.4% | 1.1–9.5% | 0.64–8.36% | 99.6–100.0% | 99.6–100.0% | 99.7–100.0% | 99.7–100.0% |
| Age group | ||||||||
| Children ≤18 years | 36.2% | 37.6% | 36.3% | 36.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| 95% CI | 27.0–45.4% | 27.3–47.9% | 27.4–45.3% | 27.9–45.9% | 0.0–0.4% | 0.0–0.4% | 0.0–0.3% | 0.0–0.3% |
| Adults ≥50 years | 64.8% | 62.4% | 63.7% | 63.1% | 100.0% | 100.0% | 100.0% | 100.0% |
| 95% CI | 54.8–73.2% | 51.7–72.3% | 54.75–72.65% | 54.1–72.1% | 99.6–100.0% | 99.6–100.0% | 99.7–100.0% | 99.7–100.0% |
| Patient setting | ||||||||
| Inpatient | 13.3% | 9.4% | 12.4% | 12.6% | 41.2% | 50.0% | 47.6% | 45.9% |
| 95% CI | 6.8–19.8% | 3.2–15.6% | 6.27–18.53% | 6.4–18.8% | 24.7–57.8% | 32.1–67.9% | 32.5–62.7% | 29.8–62.0% |
| Outpatient | 86.7% | 90.6% | 87.6% | 87.4% | 58.8% | 50.0% | 52.4% | 54.1% |
| 95% CI | 80.2–93.2% | 84.4–96.8% | 81.47–93.73% | 81.2–93.6% | 42.3–75.3% | 32.1–67.9% | 37.3–67.5% | 38.0–70.2% |
| Isolate source | ||||||||
| Skin | 87.6% | 85.9% | 88.5% | 88.3% | 50.0% | 53.3% | 47.6% | 48.6% |
| 95% CI | 81.3–93.9% | 78.5–93.3% | 82.57–94.43% | 82.3–94.3% | 33.2–66.8% | 35.5–71.2% | 32.5–62.7% | 32.5–64.7% |
| Nonskin | 12.4% | 14.1% | 11.5% | 11.7% | 50.0% | 46.7% | 52.4% | 51.4% |
| 95% CI | 6.1–18.7% | 6.7–21.5% | 5.57–17.43% | 5.7–17.7% | 33.2–66.8% | 28.9–64.6% | 37.3–67.5% | 35.3–67.5% |
A total of 170 MRSA isolates were analyzed.
PVL, Panton-Valentine Leukocidin genes.

Venn diagram showing the overlapping representations of the USA300 lineage (107 isolates that are methicillin-resistant Staphylococcus aureus, Panton-Valentine Leukocidin positive, and multilocus sequence typing [MLST] ST8, MLST CC8, staphylococcal protein A (spa) type 008, and/or spa CC008) as identified using four different typing methods: MLST CC8, MLST ST8, spa type t008, and spa CC008.